Trial intelligence / Profile preview

SAR407899 in microvascular angina or persistent stable angina after successful PCI

2016-000629-38Phase 2Completed

Sponsor
Sanofi
Start
Jun 2017
Modality
Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial in microvascular angina (MVA) and stable angina comparing SAR407899 with Placebo (2 arms). Primary endpoint: Change in uncorrected global coronary flow reserve. Started Jun 2017; status: completed.

02

Drugs

SAR407899
03

Conditions

microvascular angina (MVA)stable angina

Beyond the preview

Go deeper on 2016-000629-38.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-000629-38.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call